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AbStRACt
objective: to investigate the prevalence of IgM, Igg and IgA anti-phosphatidylserine 
(aPS) antibodies in patients with primary antiphospholipid syndrome (PAPS) and in healthy 
controls;	to	analyze	sensitivity,	and	specificity	of	aPS	antibodies	for	the	diagnosis	of	APS	and	
finally	to	assess	associations	between	aPS	antibodies	with	specific	APS	manifestations.
Methods: A cross-sectional study was performed in 36 female PAPS patients and in 200 
blood donors. IgM, Igg, and IgA antiphosphatidylserine (aPS) antibodies were tested in 
PAPS patients and controls using an in house technique and a commercial kit. PAPS pa-
tients were also tested for lupus anticoagulant (lAC), IgM and Igg anticardiolipin (aCl) 
antibodies, and for anti-β2 glycoprotein I (anti-β2gPI) antibodies.  
Results: the prevalence of IgM, Igg, and IgA aPS antibodies in PAPS patients was as 
follows: 10.8-16.7%, 32.4-35.7%, and 16.1%, respectively. Although a relatively low sen-
sitivity	was	found	for	aPS	antibodies	in	PAPS,	the	specificity	of	IgM,	IgG,	and	IgA	aPS	an-
tibodies for PAPS was 94.7-98.9%, 95.3-96.3%, and 97.9%, respectively. All aPS isotypes 
were	 significantly	 associated	with	 obstetric	manifestations	 of	 APS.	 IgM	 aPS	 antibodies	
were associated with an increased risk of venous and arterial thrombosis. IgA aPS antibo-
dies were associated with arterial thrombosis whereas Igg aPS antibodies were associa-
ted with an increased risk of venous thrombotic events. IgM and Igg aPS antibodies were 
frequently found in association with anti-β2gPI antibodies.   
Conclusions: the prevalence of aPS antibodies is low in PAPS but these antibodies are 
highly	specific	for	PAPS	and	are	associated	with	specific	PAPS	manifestations.
ANtICUERPoS ANtIFoSFAtIDIlSERINA EN PACIENtES CoN SíN-
DRoME ANtI FoSFolIPIDo PRIMARIo y EN INDIvIDUoS SANoS
RESUMEN
objetivo: Investigar la prevalencia de anticuerpos anti-fosfatidilserina (aFS) de tipo IgM, 
Igg e IgA en pacientes con síndrome antifosfolípido primario (SAFP) y en controles sanos; 
analizar	la	sensibilidad	y	la	especificidad	de	los	anticuerpos	aFS	para	el	diagnóstico	de	
aFS	 y	 finalmente,	 evaluar	 las	 asociaciones	 entre	 los	 anticuerpos	 específicos	 aFS	 y	 las	
manifestaciones clínicas del SAF.
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Pt in APS patients or antibodies against anionic PS in 
patients	classified	as	primary	APS	(PAPS)10-14.
 the aims of this study were to investigate the preva-
lence of IgM, Igg, and IgA aPS antibodies in patients 
with PAPS and in healthy controls; to analyze sensi-
tivity,	 specificity	 of	 aPS	 antibodies	 for	 the	 diagnosis	
of APS; and to assess possible associations between 
aPS	antibodies	and	specific	APS	manifestations.			
MAtERIAlS AND MEthoDS
Study population
 PAPS patients comprised 36 females with a mean 
age	of	38.4	±	11.8	years	fulfilling	the	Sapporo	criteria	
for APS.15 A total of 200 blood donors from São Pau-
lo, Brazil were included after being considered healthy 
according to a clinical questionnaire to investigate cu-
rrent or past autoimmune rheumatic disease, serious 
chronic	 infections,	and	neoplasia.	All	controls	 fulfilled	
the	 following	 inclusion	criteria:	 1)	Age	≥	18	years;	 2)	
Negative serology for HIV, hepatitis B, and hepatitis C 
infection; 3) No regular use of medication. All samples 
used in this study were selected from a serum bank at 
Universidade Federal de São Paulo and all participants 
signed the consent form approved by the Institution‘s 
ethics Committee.
INtRoDUCtIoN
 the antiphospholipid syndrome (APS) is charac-
terized by venous, arterial or microvessel thrombosis 
and/or pregnancy morbidity in the presence of anti-
phospholipid (APl) antibodies. Manifestations such as 
thrombocytopenia, hemolytic anemia, heart valve di-
sease, renal thrombotic microangiopathy, livedo reticu-
laris among others are also considered as APS-related 
manifestations1,2. APl antibodies are a heterogeneous 
class of autoantibodies directed against anionic phos-
pholipids, phospholipid-associated proteins and phos-
pholipid-protein complexes (e.g., β2 glycoprotein I and 
prothrombin)3. to date, the APl antibodies recognized 
as	APS	markers	for	clinical	classification	purposes	are	
lupus anticoagulant (lAC), anticardiolipin (aCl) anti-
bodies, and anti-β2 glycoprotein I (anti-β2gPI) anti-
bodies4-6. Nonetheless, the association between APS 
manifestations and other APl antibodies has been 
reported in the literature as well, including antibodies 
against phosphatidylserine (aPS) and against phos-
phatidylserine/prothrombin complex (aPS/Pt)3,7.  
 Phosphatidylserine (PS) is an anionic phospholipid 
with a similar structure to cardiolipin except for the pre-
sence of a serine instead of a second glycerol group 
found in the cardiolipin molecule3. the pathogenic 
role of aPS antibodies has been highlighted in expe-
rimental studies with the development of APS features 
such as thrombocytopenia, prolonged activated partial 
thromboplastin time (aPtt), and increased rate of fe-
tal resorption in mice immunized with Igg but not IgM 
aPS antibodies8,9. In the literature, a few studies have 
evaluated either antibodies against the complex aPS/
Métodos: estudio transversal de 36 pacientes mujeres con SAFP y 200 donantes de san-
gre. Se determinaron anticuerpos antifosfatidilserina de tipo IgM, Igg e IgA en pacientes 
y controles con SAFP utilizando una técnica propia y un kit comercial. A los pacientes con 
SAFP también se les determinó el anticoagulante lúpico (ACl), los anticuerpos anticardio-
lipina IgM e Igg (aCl), y los anticuerpos anti-β2 glucoproteína I (anti-β2gPI).
Resultados: la prevalencia de los anticuerpos AFS IgM, Igg, IgA en pacientes  con SAFP 
fue la siguiente: 10,8-16,7%, 32,4-35,7%, y 16,1%, respectivamente. Aunque se encontró 
una	sensibilidad	relativamente	baja	para	los	anticuerpos	AFS	en		el	SAFP,	la	especificidad	
de los anticuerpos AFS IgM, Igg, IgA  para el SAFP fue 94,7-98,9%, 95,3-96,3% y 97,9%, 
respectivamente.	Todos	los	isotipos	de	AFS	se	asociaron	significativamente	con	las	mani-
festaciones obstétricas. los anticuerpos  AFS IgM se asociaron con un riesgo aumentado 
de trombosis venosa y arterial. los anticuerpos AFS IgA se asociaron con la trombosis 
arterial mientras que los anticuerpos AFS Igg  se asociaron con un mayor riesgo de even-
tos trombóticos venosos. los anticuerpos AFS IgM e Igg se encuentran con frecuencia en 
asociación con anticuerpos anti-β2gPI.
Conclusiones: la prevalencia de anticuerpos AFS es baja en SAFS pero estos anticuer-
pos	son	altamente	específicos	para	SAFP	y	se	asocian	con	manifestaciones	SAFP	específicos.
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times with 0.05% PBS-tween 20, wells were incubated 
with	100μL	alkaline	phosphatase–conjugated	IgG,	IgM	
or IgA goat anti–human antibodies (Sigma-Aldrich Co., 
St. louis, USA) diluted 1:9000, 1:6000, and 1:1000, res- 
pectively in 0.5% PBS-BSA for 1 hour at 37ºC. Wells 
were then washed in 0.05% PBS-tween 20 and incu-
bated	 with	 100μL	 tetramethylbenzidine	 (TMB)	 subs-
trate (Siemens Healthcare, Marburg, germany) for 20 
minutes at room temperature and read at 450nm in a 
VictortM x3 microplate spectrophotometer (Perkinel-
mer Inc, Massachusetts, USA). 
 For the in house anti-phosphatidilserine elISA, 
SpetraPlatetM medium protein-binding plates (Perkin 
Elmer,	 Massachusetts,	 USA)	 were	 coated	 with	 5μg/
ml 1,2-Diacyl-sn-glycero-3-phospho-l-serine (Sigma-
Aldrich Co., St. louis, USA) in ethanol PA overnight at 
2-8°C. Next, the plates were blocked with PBS contai-
ning 30% BSA for two hours at room temperature. After 
washing 3 times with cold PBS, serum samples diluted 
1:50 in PBS and 30% BSA were incubated for 1 hour 
at room temperature. After washing 5 times with cold 
PBS	wells	 were	 incubated	with	 100μL	 alkaline	 phos-
phatase–conjugated Igg, IgM or IgA goat anti–human 
antibodies (Sigma-Aldrich Co., St. louis, USA) diluted 
at 1:9000, 1:6000, and 1:1000, respectively in PBS and 
30% BSA for 1 hour at 37ºC. Wells were then washed 
in	 cold	 PBS	 as	 before	 and	 incubated	with	 100μL	 te-
tramethylbenzidine (tMB) substrate (Siemens Health-
care, Marburg, germany) for 20 minutes at room tem-
perature and read at 450nm in a VictortM x3 microplate 
spectrophotometer (Perkinelmer Inc, Massachusetts, 
USA). the cut-off value was established as the mean 
plus two standard deviations from 8 negative samples. 
Results were provided as the index obtained by divi-
ding the test sample by the cut-off value. A positive 
result	was	considered	if	index	was	≥1.0.
Statistical analysis
 Statistical analysis was carried out with the SPSS 
software (SPSS Inc, PASW Statistics for Windows, 
Version 18.0, Chicago, USA). Numerical data were 
displayed as mean, median, standard deviation, inter-
quartile	range	or	95%	confidence	interval	(95%	CI)	as	
appropriate, while categorical data were presented as 
total	number	and	percentage.	Analysis	 for	significant	
differences between groups were performed using the 
Chi square test for categorical variables, while asso-
ciations	between	 specific	 isotypes	 of	 aPS	 antibodies	
with an increased risk of thrombosis or obstetric mani-
festations of APS were assessed by univariate logistic 
regression analysis and results were displayed in odds 
ratio (oR) and 95% CI. All analysis for diagnostic per-
Antiphospholipid antibodies
 enzyme-linked immunosorbent assays (elISA) were 
performed according to the manufacturer’s operating 
instructions using commercial kits for the following: Igg 
and IgM aCl from DiaSorin (Saluggia, Italy) IgA aCl 
from Varelisa® (Phadia gmbH, Freiburg, germany), 
IgM and Igg anti-β2gPI from the Binding Site (Birming-
ham, UK), and Igg and IgM aPS from orgentec Diag-
nostika gmbH (Mainz, germany). lAC was detected 
using aPtt from Diagnostica Stago, France and diluted 
Russel’s viper venon time (dRVVt) from trinity Biotech, 
Wiclow, Ireland, according to the guidelines of the In-
ternational Society of thrombosis and Haemostasis16. 
 In addition, aCl (IgM and Igg), aPS (Igg, IgM, 
and IgA) and anti-β2gPI (Igg, IgM, and IgA) in house 
elISAs were performed as previously described with 
some	modifications.17,18	Briefly,	the	in	house	aCL	ELISA	
test was performed with elISA plates NUNC (thermo 
Fisher	Scientific	Inc.,	Roskilde,	Denmark)	coated	with	
bovine cardiolipin 50 µg/ml (Sigma-Aldrich, St. louis, 
USA) and blocked with 10% adult bovine serum in 
saline at neutral pH for an hour. Plates were incuba-
ted overnight at 4°C with 50µl of serum diluted in PBS 
and 10% bovine serum albumin (BSA) at 1:50 dilution. 
then, three washes were performed with PBS, and 50µl 
of conjugated anti-human Igg or IgM (Calbiochem, la 
Jolla, California, USA) was added to the plate. then 
plates were incubated for 90 minutes at room tempera-
ture. After further washing steps, we added 50µl of de-
veloping solution and the plate was incubated at room 
temperature, protected from light for 30 minutes. the 
reading was performed with a spectrophotometer at a 
wavelength of 450 nanometers (nm). We constructed a 
calibration curve using international standards (louis-
ville APl Diagnostics Inc, Doraville United States, Prod 
# lAPl-gM100 Igg / IgM Calibrators). Values in optical 
density were interpolated this calibration curve and an 
equation was generated to provide results in units gPl 
and MPl. 
The in house anti-β2GPI ELISA test was performed 
as follows: NUNC Maxisorp plates (Nalge Nunc Inter-
national,	Rochester,	NY)	were	coated	with	5μg/mL	β2-
glycoprotein I (Meridian life Science, Inc. Memphis, 
USA) in PBS overnight at 2-8ºC. Plates were washed 
with 0.05% PBS-tween 20 and 200µl of 0.5% PBS-
BSA was added to wells and incubated during one 
hour at room temperature. After washing 3 times with 
0.05% PBS-tween 20, 50µl of serum dilutions repre-
senting six points of the standard curve (louisville, APl 
Diagnostics, Inc. - Doraville, USA) and serum samples, 
all diluted 1:50 in 0.5% PBS-BSA were incubated for 1 
hour at room temperature. After washing the plates 5 
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Clinical features and aPS antibodies in PAPS pa-
tients
 thrombosis was the most common manifestation, 
being observed in 30 (83.3%) PAPS patients. Venous 
thrombosis was found in 16 (44.4%), arterial throm-
bosis in 13 (36.1%) and pulmonary embolism in 4 
(11.1%). Ischemic stroke was the most common ar-
terial thrombotic event, observed in 10 (27.8%) PAPS 
patients. obstetric manifestations were found in 17 
patients (47.2%) and they were the sole APS manifes-
tation in 6 (36.6%) patients. According to univariate 
analysis	all	aPS	isotypes	were	significantly	associated	
with obstetric manifestations of APS. In contrast, the 
aPS isotypes behaved differently regarding the risk of 
thrombotic events. IgM aPS antibodies were strongly 
associated with an increased risk of venous thrombo-
sis but they had a marginal association with arterial 
thrombosis. IgA aPS antibodies were associated with 
arterial thrombosis whereas Igg aPS antibodies were 
associated with an increased risk of venous thrombotic 
events (table 3). No associations were found between 
disease manifestations and anti-β2gPI antibodies. 
formance and clinical associations regarding aPS an-
tibodies were performed using the in house technique 
as a reference while for the associations between aPS 
and different aPl antibodies, using either commercial 
kits and in house technique were analyzed with the 
Kappa	 coefficient	 and	 Spearman	 correlation	 coeffi- 
cient.	Level	of	significance	accepted	was	5%	(p< 0.05). 
  
RESUltS
aPS antibodies in PAPS patients and in control sub-
jects
 the positivity of any aPS antibody was 44.0% in PAPS 
patients and amongst them, 62.5% had more than one 
isotype of antibodies against PS. the prevalence of IgM, 
IgG,	and	IgA	aPS	antibodies	was	significantly	higher	in	
PAPS than in controls for most isotypes (table 1). even 
though a low sensitivity in the diagnosis of PAPS was 
observed	 for	 all	 aPS	 isotypes,	 the	 specificity,	 positive	
predictive value, and negative predic-tive value for the 
diagnosis of PAPS were quite high for both the in house 
technique or the commercial elISA (table 2). However, 
IgM aPS antibodies detected by the commercial elISA 
kit yielded the lowest positive predictive value for PAPS.  
variables
Positive IgM aPS, n (%)
Positive Igg aPS, n (%)
Positive IgA aPS, n (%)
Positive IgM aPS, n (%)
Positive Igg aPS, n (%)
table 1 the prevalence of IgM, Igg and IgA antiphosphatidylserine antibodies in PAPS and in controls evaluated by the in house assay
Control subjects
2 (1.0)
7 (3.6)
4 (2.1)
8 (5.2)
7 (4.6)
p
<0.0001
<0.0001
<0.0001
0.362
<0.0001
PAPS patients
6 (16.7)
13 (35.7)
5 (16.1)
4 (10.8)
12 (32.4)
In house assay
Commercial assay
PAPS: primary antiphospholipid syndrome.
Parameters
Sensitivity
Specificity
Positive predictive value 
Negative predictive value
table 2 Performance of aPS antibodies tests for the diagnosis of PAPS
IgG
aPS
33.3-35.1%
95.3-96.3%
63.1-65.0%
88.5-88.6%
IgA
aPS
16.1%
97.9%
55.5%
97.9%
IgM 
aPS
11.1-16.6%
94.7-98.9%
33.3-75.0%
81.8-86.4%
For IgM and Igg antiphosphatidylserine antibodies data were obtained using the in house and commercial elISA, respectively; aPS – antiphosphati-
dylserine; PAPS – primary antihospholipid syndrome.
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 A strong agreement was found between the in house 
test and the commercial kit results for Igg aPS (Kappa 
coefficient	=	0.875;	p < 0.0001) and accordingly there
was a strong correlation between titers of Igg aPS 
antibodies in the two elISA systems (ρ	 =	 0.763;	
p < 0.0001). eleven out of 12 patients had positive re-
sults for Igg aPS antibodies when using the in house 
test and the commercial kit while only 2 out of 12 pa-
tients with IgM aPS antibodies were positive in both 
methods (Figures 1 and 2). In contrast there was no 
significant	 correlation	 between	 the	 in	 house	 test	 and	
the	co-mmercial	 kit	 for	 IgM	aPS	 (kappa	coefficient	=	
0.204; p =	 0.211)	 and	 accordingly	 there	was	 no	 co-
rrelation between the titers of IgM aPS in the two elI-
SA systems. An association between Igg aPS and Igg 
Association between aPS antibodies and other aPl 
antibodies
 In a cross-sectional analysis, the prevalence of each 
aPl antibody test in PAPS patients varied accordingt o 
the use of in house assays and commercial kits, as 
follows: lAC 18 (50%), IgM aCl antibodies (5.6-27.8%), 
Igg aCl antibodies (33.3-38.9%), IgM anti-β2gPI 
(13.9-22.2%), Igg anti-β2gPI (13.9-27.8%), IgM aPS 
(13.9-19.4%), Igg aPS (33.3%) and IgA aPS (13.9%) 
(table 4). In the longitudinal analysis of aCl tests re-
peated along time in PAPS patients, the prevalence of 
IgM and Igg aCl was 38.9% and 88.9%, respectively. 
the prevalence of triple positive PAPS patients (i.e. 
positivity of aCl, lAC, and anti-β2gPI) was 36.1% in this
series. 
aPS isotypes
IgM aPS
Igg aPS
IgA aPS
IgM aPS
Igg aPS
IgA aPS
IgM aPS
Igg aPS
IgA aPS
table 3 Risk for APS manifestations associated with each isotype of aPS antibodies in univariate analysis*
95% confidence interval
3.29-58.39
1.97-21.19
0.83-23.54
1.00-29.25
0.93-15.01
1.32-41.40
 
1.66-32.57
2.66-26.16
1.74-34.64
p
<0.0001**
0.002**
0.080
0.049**
0.062
0.023**
0.009**
<0.0001**
0.007**
odds ratio
13.86
6.46
4.44
5.42
3.75
7.39
7.35
8.35
7.76
venous thrombosis
*data	obtained	with	in	house	ELISA;	**Significant	results;	aPS	–	antiphosphatidylserine	antibodies.
Arterial thrombosis   
Obstetric manifestations
IgM aPS
Figure 1 Positivity of IgM aPS antibodies in PAPS patients using the in 
house test and a commercial kit.
Positive in both  
Positive in house test
Positive commercial 
assay
Negative
Igg aPS
Figure 2 Positivity of Igg aPS antibodies in PAPS patients using the in 
house test and a commercial kit.
Positive in both  
Positive in house test
Positive commercial 
assay
Negative
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 We found a prevalence of aPS antibodies lower than 
previously described for IgM aPS (50.0-77.0%) and 
Igg aPS (45.4-60.0%) in PAPS patients13,14. Similarly to 
previous studies that included Brazilian patients with 
PAPS19-21, the most prevalent aPl antibodies tests in this 
study were lAC and Igg aCl, and that might indicate 
a higher burden of these aPl antibodies rather than 
aPS antibodies in Brazilian patients with PAPS. Among 
controls evaluated in this study, the prevalence of aPS 
was similar to the 2% described for both Igg and IgM 
aPS13. the frequency of IgA aPS antibodies was simi-
lar to IgM aPS in the present series of PAPS patients 
whereas Radway-Bright et al could not detect IgA aPS 
in PAPS patients, but only in patients with systemic lu-
pus erythematosus (Sle) (4%) and in APS associated 
with Sle (12%)13. the detection of aPS antibodies may 
not be regarded as a routinely useful diagnostic tool 
for APS due its low sensitivity. However, due to its high 
specificity	 for	 PAPS,	 the	 detection	 of	 aPS	 antibodies	
could be useful in patients with the so-called serone-
gative APS, in other words testing for aPS antibodies 
would only be worth when all other aPl antibodies are 
repetitively negative in a patients with suspicious APS. 
	 Associations	between	aPS	antibodies	and	specific	
manifestations of APS have been observed in several 
studies. Arterial thrombosis is a severe manifestation 
of APS and usually affects the central nervous system 
occurring as stroke or transient ischemic attacks1,2. 
anti-β2gPI antibodies was found using the in house 
assay for aPS antibodies (table 5) and their titers were 
significantly	correlated	as	well	 (ρ	=	0.675;	p	=	0.001).	
No association was found between IgM or IgA aPS anti-
bodies determined with the in house method and other 
tests for aPl antibodies. Nonetheless, using commercial 
kits for aPS, we observed that IgM and Igg aPS were 
associated with both IgM and Igg anti- β2gPI (table 6).
DISCUSSIoN
 In this study, we have evaluated the role of aPS an-
tibodies in the diagnosis of PAPS and the associations 
between IgM, Igg and IgA aPS antibodies with APS 
manifestations and other aPl antibodies. Although all 
isotypes of aPS antibodies had a low sensitivity, they 
were	all	highly	specific	for	the	diagnosis	of	PAPS.	Mo-
reover, IgM aPS antibodies were associated with an 
increased risk of venous and arterial thrombotic events 
while Igg aPS antibodies were associated with venous 
thrombosis and IgA aPS antibodies with arterial throm-
bosis. All isotypes of aPS antibodies were associated 
with obstetric manifestations of PAPS. Results obtained 
from the in house technique and from a commercial 
assay kit were very similar for Igg aPS antibodies while 
we	 could	 not	 find	 any	 significant	 agreement	 for	 IgM	
aPS. An association between aPS antibodies and anti-
β2gPI antibodies was observed as well.
Anti-phospholipid antibody 
and type of assay
In house IgM aCl 
In house Igg aCl 
Commercial IgM aCl test 
Commercial Igg aCl test
In house	IgM	anti-β2	GPI	
In house	IgG	anti-β2	GPI	
Commercial	IgM	anti-β2	GPI
Commercial	IgG	anti-β2	GPI
In house IgM aPS 
In house Igg aPS 
In house IgA aPS 
Commercial IgM aPS test
Commercial Igg aPS test
table 4 Behavior of several anti-phospohlipid antibodies in PAPS patients according to the type of assay  
Frequency of positive results
10 (27.8%)
14 (38.9%)
2 (5.6%)
12 (33.3%)
8 (22.2%)
10 (27.8%)
5 (13.9%)
5 (13.9%)
7 (19.4%)
12 (33.3%)
5 (13.9%)
5 (13.9%)
12 (33.3%)
Median or mean titer
33.0 (23.0-92.2) MPl
74.5 ± 20.8 gPl
62.5 (25.0-100.0) MPl
66.2 ± 24.8 gPl
23.0 (19.5-52.0) U/ml
18.0 (8.0-51.0) U/ml
24.0 (17.5-184.5) U/ml
55.5 (20.5-162.7) U/ml
0.52 (0.32-0.87)
0.01 (0.01-4.56)
0.64 (0.45-0.79)
-3.46 (-6.79-1.13)
3.77 (0.96-35.86)
Data are presented as mean ± standard deviation for normally distributed variables and as median and interquartile range for non-normally distri-
buted	variables;	anti-β2	GPI	–	anti-β2	glycoprotein	I;	aCL	–	anticardiolipin;	aPS	–	antiphosphatidylserine.
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dinal study that included 223 follow-up samples of 45 
APS patients along ten years24. 
 In this study, we could observe an association 
between IgM aPS antibodies with venous thrombosis 
but not with other isotypes of aPS. on the other hand, 
lopez et al found an increased risk of venous thrombo-
sis with IgM (oR: 9.6; 95% CI: 2.0-46.3; p	=	0.003)	and	
Igg (oR: 21.0; 95% CI: 2.6-170.1; p < 0.001) but not 
with the IgA isotype aPS antibodies in APS patients.22 
However,	no	significant	association	between	aPS	anti-
bodies and venous thrombosis could be seen a longi-
tudinal study in APS.24  Regarding obstetric manifesta-
tions, all isotypes of aPS antibodies were associated 
with an increased risk of pregnancy morbidity in PAPS 
in the present series and similar oR values were ob-
served among the three isotypes. In the literature, the 
association between aPS antibodies and obstetric ma-
nifestations of has been strong for Igg aPS. In fact the-
We	 found	a	 significant	 association	between	 IgM	and	
IgA isotypes of aPS antibodies with arterial thrombosis 
in PAPS patients while a trend for an association was 
found with Igg aPS antibodies. Controversial results 
regarding the association of aPS isotypes with stroke 
have been found in literature. two cross-sectional stu-
dies	have	evaluated	aPS	antibodies	with	specific	APS	
manifestations. lopez et al found an increased risk 
of arterial thrombosis in APS patients presenting IgM 
(oR: 13.8; 95% CI: 2.9-63.9; p < 0.001) or Igg (oR: 
35.8; 95% CI: 4.5-282.7; p < 0.001) aPS antibodies but 
not for IgA aPS. In contrast, Mucial et al found only an 
association between IgM aPS antibodies with throm-
bocytopenia.14,22 In assorted patients presenting stroke 
without a previous diagnosis of APS, a higher preva-
lence of Igg aPS antibodies was found in comparison 
with control subjects (57.7% vs. 4.8%, p < 0.001)23. In 
addition, Roggenbuck et al observed an association 
between IgM aPS and arterial thrombosis in a longitu-
variables
lAC, n (%)
IgM aCl, n (%)
Igg aCl, n (%)
IgM	a.β2GPI,	n	(%)
IgG		a.β2GPI,	n	(%)
triple positive  
patients, n (%)
table 5 Associations between anti-phosphatidylserine antibodies (aPS) detected by in house assay and anti-phospholipid antibodies accepted as  
classification	criteria	for	anti-phospholipid	syndrome
IgM aPS IgG aPS
Positive
(n=7)
3 (42.9)
4 (57.1)
7 (100.0)
2 (28.6)
3 (42.9)
3 (42.9)
Negative
(n=29)
15 (51.7)
10 (34.5)
25 (86.2)
10 (34.5)
10 (34.5)
10 (34.5)
p
0.500
0.248
0.403
0.571
0.499
0.499
Positive
(n=12)
5 (41.7)
4 (33.3)
12 (100.0)
6 (50.0)
8 (66.7)
6 (50.0)
Negative
(n=24)
13 (54.2)
10 (41.7)
20 (83.3)
6 (25.0)
5 (20.8)
7 (29.2)
p
0.480
0.456
0.180
0.134
0.010**
0.220
**Significant	results;	anti-β2	GPI	–	anti-β2	glycoprotein	I;	aCL	–	anticardiolipin;	aPS	–	antiphosphatidylserine;	LAC	–	lupus	anticoagulant.
variables
lAC, n (%)
IgM aCl, n (%)
Igg aCl, n (%)
IgM	a.β2GPI,	n	(%)
IgG		a.β2GPI,	n	(%)
triple positive  
patients, n (%)
table 6 Associations between anti-phosphatidylserine antibodies (aPS) detected by commercial assays and anti-phospholipid antibodies accep-
ted	as	classification	criteria	for	APS
IgM aPS IgG aPS
Positive
(n=5)
3 (60.0)
3 (60.0)
5 (100.0)
4 (80.0)
4 (80.0)
3 (60.0)
Negative
(n=31)
15 (48.4)
11 (35.5)
27 (87.1)
8 (25.8)
9 (29.0)
10 (32.3)
p
0.500
0.287
0.534
0.034**
0.047**
0.239
Positive
(n=12)
6 (50.0)
4 (33.3)
12 (100.0)
7 (58.3)
9 (75.0)
7 (58.3)
Negative
(n=24)
12 (50.0)
10 (41.7)
20 (83.3)
5 (20.8)
4 (16.7)
6 (25.0)
p
0.638
0.456
0.180
0.024**
0.001**
0.050
**Significant	results;	anti-β2	GPI	–	anti-β2	glycoprotein	I;	aCL	–	anticardiolipin;	aPS	–	antiphosphatidylserine;	LAC	–	lupus	anticoagulant.
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5. opatrny l, David M, Khan SR, Shrier I, Rey e. Association between 
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 without autoimmune diseases: a metaanalysis. J Rheumatol. 2006; 
 33(11):2214-21.
6.	 Galli	M,	Borrelli	G,	Jacobsen	EM,	Marfisi	RM,	Finazzi	G,	Marchiori	R,	 
	 et	al.	Clinical	 significance	of	different	antiphospholipid	antibodies	 
 in the WAPS (warfarin in the antiphospholipid syndrome) study. 
 Blood. 2007;110(4):1178-83. 
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 autoantigens in the antiphospholipid syndrome. Autoimmun Rev. 
 2011;10(10):609-16.
8. Blank M, tincani A, Shoenfeld Y. Induction of experimental anti- 
	 phospholipid	 syndrome	 in	 naïve	mice	with	purified	 IgG	antiphos- 
 phatidylserine antibodies. J Rheumatol. 1994;21(1):100-4.
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 anti-phosphatidylserine antibodies: active immunization with the 
 antibodies lead to the induction of the antiphospholipid syndrome. 
 Clin Immunol Immunopathol. 1996;78(1):14-20.
10. Atsumi t, Ieko M, Bertolaccini Ml, Ichikawa K, tsutsumi A, 
 Matsuura e, et al. Association of autoantibodies against the 
 phosphatidylserine-prothrombin complex with manifestations of the 
 antiphospholipid syndrome and with the presence of lupus anti- 
 coagulant. Arthritis Rheum. 2000;43(9):1982-93.
11. Hoxha A, Ruffatti A, tonello M, Bontadi A, Salvan e, Banzato A, et al. 
 Antiphosphatidylserine/prothrombin antibodies in primary antiphos- 
 pholipid syndrome. lupus. 2012;21(7):787-9.
12. Vlagea AD, gil A, Cuesta MV, Arribas F, Diez J, lavilla P, et al. 
 Antiphosphatidylserine/prothrombin antibodies (aPS/Pt) as 
 potential markers of antiphospholipid syndrome. Clin Appl thromb 
 Haemost. 2012. Available from ttp://cat.sagepub.com/content/ 
 early/2012/02/27/1076029612437578.long [Accessed on September 
 17th 2012].
13. Radway-Bright e, Ravirajan Ct, Isenberg DA. the prevalence of 
 antibodies to anionic phospholipids in patients with the primary 
 antiphospholipid syndrome, systemic lupus erythematosus and 
 their relatives and spouses. Rheumatology (oxford). 2000; 
 39(4):427-31.
14.	Musial	 J,	 Swadzba	 J,	Motyl	 A,	 Iwaniec	 T.	Clinical	 significance	 of	 
 antiphospholipid protein antibodies. Receiver operating 
 characteristics plot analysis. J Rheumatol. 2003;30(4):723-30.   
15. Wilson WA, gharavi Ae, Koike t, lockshin MD, Branch DW, Piette 
 JC, et al. International consensus statement on preliminary 
	 classification	criteria	for	definite	antiphospholipid	syndrome:	report	 
 of an international workshop. Arthritis Rheum. 1999;42(7):1309-11.
16. Pengo V, tripodi A, Reber g, Rand JH, ortel tl, galli M, et al. 
 Update of the guidelines for lupus anticoagulant detection. 
 Subcommittee on lupus Anticoagulant/Antiphospholipid Antibody 
	 of	 the	 Scientific	 and	 Standardisation	 Committee	 of	 the	 International	 
 Society on thrombosis and Haemostasis. J thromb Haemost. 2009; 
 7(10):1737-40.
17. gharavi Ae, Harris eN, Asherson RA, Hughes gR. Anticardiolipin 
	 antibodies:	 isotype	 distribution	 and	 phospholipid	 specificity.	 Ann	 
 Rheum Dis. 1987;46(1):1-6.
18. Viard JP, Amoura Z, Bach JF. Anti-b2-glycoprotein I antibodies and 
 thrombosis. Clin Rev Allergy Immunol. 1995;13(1):67-72.
se autoantibodies may be the sole positive test found in 
women with negative tests for other aPl antibodies24-26.  
 Standardization of aPl antibodies tests has been an 
issue for the diagnosis of aPS and that may account 
for the heterogeneous results in different reports27.  In 
the present study some differences could be obser-
ved in results obtained by the use of in house assays 
and commercial kits for aCl, anti-β2gPI, and IgM aPS 
antibodies. However, good correlations regarding 
the positivity and oD values were observed between 
the in house and the commercial assay for Igg aPS 
antibodies.
   
	 This	is	the	first	time	that	an	association	is	demonstra- 
ted between IgM and Igg aPS antibodies with IgM and 
Igg anti-β2gPI antibodies, especially when using the 
commercial kit for aPS. Previously, IgM and Igg aPS 
had been found in association with IgM and Igg aCl 
antibodies, respectively14. thus both aPl antibodies 
may account together for the increased risk observed 
for APS manifestations with aPS antibodies. the lack of 
association between aPS antibodies and triple positive 
patients may indicate that the presence of aPS anti-
bodies is not necessarily connected to an excessive 
multiproduction of aPl antibodies.
 In conclusion, aPS antibodies seem to display low 
sensitivity	and	high	specificity	 for	 the	classification	of	
PAPS. IgM aPS antibodies were associated with an in-
creased risk of arterial and venous thrombotic events, 
while Igg aPS antibodies were associated with venous 
thrombosis, and IgA aPS antibodies were associated 
with arterial events. All aPS isotypes were shown to be 
a risk factor for obstetric manifestations of APS. Igg 
and IgM aPS antibodies were associated with IgM and 
Igg anti-β2gPI antibodies in PAPS patients. the de-
tection of aPS antibodies does not seem to present any 
advantage over other APl antibody tests and may be 
of value in patients with suspicious APS without positive 
APl tests.
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